Martin Zenni, MD

Sirolimus-Eluting Stents for Treatment of Complex Bypass Graft Disease: Insights from the SECURE Registry

08/01/2008

Marco A. Costa , MD, PhD;

Andrew J. Carter , DO, FACC;

Paul S. Teirstein , MD, FACC;

Martin B. Leon , MD;

Martin Zenni , MD;

Theodore A. Bass , MD;

Steven J. Yakubov , MD;

Paul Gilmore , MD;

Jeffrey W. Moses , MD;

Tim A. Fischell , MD, FACC, FSCAI;

Dominick J. Angiolillo , MD, PhD;

Treatment options for bypass graft disease, such as repeat CABG and percutaneous revascularization, are limited and provide disappointing outcomes.1-4 Patients undergoing repeat CABG have over a four times greater rate of mortality compared...

Treatment options for bypass...

08/01/2008

Journal of Invasive Cardiology

The Use of Tirofiban in ACS Patients

10/07/2016

Martin Zenni , MD;

A new, more concentrated format of tirofiban will soon become available to deliver the FDA-approved, high-dose bolus of 25 mcg/kg at the start of treatment: pre-mixed, ready-to-use, 250 mcg/mL in a 15 mL vial.

A new, more concentrated format...

10/07/2016

Cath Lab Digest